MedTrace Logo

Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy

NCT02550964 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2015-09-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.

Conditions

  • Toxic Maculopathy

Interventions

PROCEDURE

Composite Examination

First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • JooYong Lee, Professor · Asan Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550964 on ClinicalTrials.gov